FDA Pushes Back Exelixis Colorectal Decision; Shares Fall 2.28%

The FDA has delayed its approval decision on Exelixis' oral tyrosine kinase inhibitor combined with Roche's Tecentriq for metastatic colorectal cancer, and Exelixis (EXEL) closed at 56.12 on Friday, down 2.28% on the day.

The Food and Drug Administration has delayed its approval decision on Exelixis' oral tyrosine kinase inhibitor for metastatic colorectal cancer, the company's most closely watched near-term regulatory event. The drug is under review in combination with Roche's Tecentriq, the PD-L1 checkpoint inhibitor that has become a standard partner in immuno-oncology combinations.

Exelixis (EXEL) last traded at 56.12, down 2.28% on Friday against a broad market that finished higher, with the S&P 500 tracker up 0.85% and the Nasdaq 100 tracker up 0.87%. Roche's American depositary receipts (RHHBY) closed at 52.75, off 0.83%. The move in Exelixis was modest by the standards of a biotech regulatory disappointment, which suggests investors read the news as a scheduling matter rather than a verdict on the data.

What a delay actually signals — and what it does not

A postponed decision is not a rejection. Under the FDA's user-fee framework, the agency commits to a target action date for each application it accepts. That date can slip for reasons that have little to do with whether a drug works: a sponsor submits additional information that the agency classifies as a major amendment, a manufacturing site needs re-inspection, reviewers want more time with statistical analyses, or the agency's own workload forces a reshuffle. Each of those paths resets the clock rather than closing the door.

What matters for shareholders is which of those it was. A delay driven by chemistry, manufacturing and controls questions is usually the most benign, because it concerns how the drug is made rather than what it does. A delay tied to the efficacy package or to the design of the supporting trial is the version that erodes confidence, because it hints that the review division is unconvinced by the evidence as filed. The reported news, as covered by Fierce Biotech, is that analysts have taken a view on the setback; the share reaction implies that view is not catastrophic.

Why colorectal cancer is the hard test

Metastatic colorectal cancer is one of oncology's most stubborn commercial and clinical problems. The majority of patients whose disease has spread have tumors that are microsatellite stable — biologically "cold" to the immune system — and checkpoint inhibitors on their own have repeatedly failed to move the needle in that group. The rationale for pairing a multi-targeted tyrosine kinase inhibitor with a PD-L1 antibody such as Tecentriq is that blocking angiogenic and immune-suppressive signaling can warm the tumor environment enough for the checkpoint drug to work.

That is a mechanism with a long history of near-misses. It is also why an approval here would carry weight well beyond a single label: it would validate the TKI-plus-checkpoint template in a tumor type where it has mostly disappointed, and it would give oncologists an oral-plus-infusion option for patients who have exhausted chemotherapy. Later-line metastatic colorectal cancer remains a large, poorly served population, which is precisely why the commercial stakes attached to this filing are not trivial.

The franchise question behind the filing

Exelixis is a company defined by a single kinase-inhibitor franchise. Its revenue base rests on cabozantinib, marketed in kidney, liver and thyroid indications, and the strategic task facing management has for years been the same: extend the franchise into new tumor types and bring forward a successor molecule before the existing patent and competitive runway narrows. A colorectal approval would be an expansion of exactly that kind.

A delayed decision does not remove the opportunity, but it does push out the revenue curve. For a company whose valuation depends on the market's willingness to underwrite future indications rather than current ones, timing is not a detail. Every quarter of slippage shifts launch spending, sales-force build-out and prescriber education into a later period, and shortens the window in which the product can build share before competing regimens arrive.

For Roche, the arithmetic is different. Tecentriq is one line in a vast portfolio, and a combination approval in colorectal cancer would be incremental — welcome, but not a needle-mover for a company of that size. That asymmetry explains the difference in the two share reactions: Exelixis closed down 2.28% and Roche's ADRs down 0.83%, the latter within the ordinary daily range of a large-cap pharmaceutical listing. Relative to the S&P 500 tracker's 0.85% gain on the day, Exelixis underperformed by roughly 3.13 percentage points — an illustrative comparison drawn from the two closing moves, not a reported figure.

What to watch from here

Three things will determine whether Friday's modest decline was the right read. First, the stated reason for the extension — sponsors typically disclose whether the agency requested additional information or flagged manufacturing issues, and that disclosure usually arrives within days. Second, the new action date, which sets the calendar for launch preparation and for any related trials. Third, whether the FDA calls an advisory committee meeting; a scheduled panel would signal that reviewers want outside opinion on the risk-benefit case, and it would introduce a public airing of the data before any decision.

Investors should also watch for any read-through to the rest of the combination's development program. Regulatory filings in oncology rarely stand alone; a molecule under review in colorectal cancer is typically being tested in parallel across other tumor types, and the arguments the agency raises in one review often echo in the next. If the extension stems from a question about trial design or endpoint choice, that question does not stay confined to one application.

For now, the position is straightforward: the application is alive, the decision has moved, and the market has priced a delay rather than a defeat. Prices cited are Friday's closing levels as of 20:00 GMT on 11 September 2026.

Key facts

• EXEL last close: 56.12, -2.28% (as of 11 Sep 2026, 20:00 GMT)
• RHHBY last close: 52.75, -0.83% (as of 11 Sep 2026, 20:00 GMT)
• Regulatory event: FDA delayed approval decision on Exelixis' oral tyrosine kinase inhibitor
• Indication: Metastatic colorectal cancer, in combination with Roche's Tecentriq

Frequently asked questions

What did the FDA actually do?

The FDA delayed its approval decision on Exelixis' oral tyrosine kinase inhibitor, which is under review in combination with Roche's Tecentriq for metastatic colorectal cancer. A delay means the agency has moved its target action date; the application remains under review and no rejection has been issued.

How did Exelixis shares respond?

Exelixis (EXEL) finished the session at 56.12, down 2.28% from its prior close of 57.43, with a day range of 54.55 to 57.43. That decline came on a day when the S&P 500 tracker rose 0.85% and the Nasdaq 100 tracker rose 0.87%, so the stock lagged a broadly positive tape.

Why does the Tecentriq combination matter in colorectal cancer?

Most metastatic colorectal tumors are microsatellite stable and respond poorly to checkpoint inhibitors used alone. Pairing a multi-targeted tyrosine kinase inhibitor with a PD-L1 antibody such as Tecentriq is intended to alter the tumor environment so the immune drug can work. Success would validate a combination approach that has repeatedly disappointed in this tumor type.

What are the usual reasons the FDA extends a decision date?

Common causes include a sponsor submitting substantial new information that the agency treats as a major amendment, outstanding manufacturing or facility inspection issues, or reviewers requesting more time with efficacy and safety analyses. Manufacturing-related delays are generally viewed as the least concerning; questions about the efficacy package carry more weight for investors.

How significant is this for Roche?

Far less than for Exelixis. Tecentriq is one product within a very large portfolio, so a colorectal combination approval would be incremental rather than transformative. Roche's American depositary receipts closed at 52.75, down 0.83%, a move consistent with ordinary daily fluctuation for a large-cap pharmaceutical listing.

What should investors watch next?

Three items: the disclosed reason for the extension, which usually emerges within days of the notification; the new target action date, which governs launch planning and spending; and whether the FDA schedules an advisory committee meeting, which would signal that reviewers want outside expert input on the risk-benefit case before deciding.

Sources

• FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer — Fierce Biotech

Photo: Edward Jenner · Pexels Licence — source